Complement Inhibitors in Atypical HUS

Introduction And Pathophysiological Rationale

Atypical Hemolytic Uremic Syndrome (aHUS) is increasingly designated as Complement-Mediated Hemolytic Uremic Syndrome (CM-HUS).
Pathogenesis heavily involves alternative complement pathway dysregulation, leading to uncontrolled C5 terminal cleavage and massive Membrane Attack Complex (MAC or C5b-9) formation.
MAC aggressively attacks host renal glomerular endothelium, inducing severe microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury.
Targeted terminal complement inhibitors replaced historical plasma exchange therapy, fundamentally shifting the prognosis from fatal end-stage kidney disease to manageable chronic remission.

Agent	Mechanism Of Action	Administration Profile	Key Clinical Features
Eculizumab	Humanized monoclonal IgG2/4 antibody directly blocking C5 cleavage into C5a/C5b, arresting MAC formation.	Intravenous induction followed by maintenance infusions strictly every 14 days.	First-in-class agent; preserves early complement pathways for immune complex clearance and partial opsonization.
Ravulizumab	Second-generation C5 inhibitor reverse-engineered for acidic endosomal recycling via neonatal Fc receptor (FcRn) binding.	Intravenous maintenance spaced every 4 to 8 weeks depending on body weight.	Four-fold half-life extension drastically improves pediatric quality of life while maintaining non-inferior efficacy.
Crovalimab	Novel recycling sequential monoclonal antibody binding an entirely alternate C5 epitope.	Small-volume subcutaneous injection every 4 weeks.	Effective in Asian variants harboring the C5 p.Arg885His mutation resistant to eculizumab; enables home administration.
Proximal Inhibitors	Halt the alternative pathway amplification loop at the origin by targeting Factor D, Factor B (Iptacopan), or C3 (Pegcetacoplan).	Oral and subcutaneous formulations undergoing advanced 2025/2026 pediatric evaluation.	Targets extravascular hemolysis driven by continuous C3 breakdown and deposition unchecked by terminal C5 inhibitors.

KDIGO and European Reference Network guidelines mandate anti-C5 therapy initiation within 24 to 48 hours of clinical suspicion.
Therapy must absolutely not be delayed pending extensive genetic sequencing results.

Acquired anti-Complement Factor H (CFH) autoantibodies drive a massive proportion of Indian pediatric aHUS cases.
Guidelines recommend a hybrid approach utilizing concurrent immunosuppression (corticosteroids, mycophenolate mofetil, or rituximab) to lower antibody titers alongside anti-C5 therapy for immediate renal protection.

Routine lifelong therapy is no longer an absolute clinical mandate.
Discontinuation is deemed safe after 6 to 12 months of remission in children lacking identified mutations or possessing low-risk isolated Membrane Cofactor Protein (MCP) mutations.
Discontinuation remains strictly discouraged in high-risk genetic profiles involving gain-of-function C3 or Complement Factor B (CFB) mutations.

Terminal complement blockade exponentially increases susceptibility to encapsulated bacterial infections, primarily Neisseria meningitidis.
Federal regulations mandate comprehensive meningococcal vaccination (MenACWY and MenB) at least 2 weeks prior to therapy initiation.
Due to the hyper-acute emergency nature of aHUS, patients initiate therapy simultaneously with vaccines, necessitating mandatory continuous antibiotic prophylaxis (Penicillin V or Macrolides).

Prohibitive costs render branded eculizumab and ravulizumab entirely inaccessible to the vast majority of the Indian pediatric demographic.
Foundational patents for eculizumab are expiring, with multiple biosimilars entering late Phase III clinical trials globally.
Impending regulatory approvals for Indian-manufactured biosimilars by 2026 are projected to trigger a massive price collapse, finally democratizing access to targeted complement inhibition for vulnerable populations.